Promising Trial | GenomeWeb

Promising Trial

PARP inhibitors finally have some proof, writes Derek Lowe at In the Pipeline. He notes that the drug class has had its ups and downs, as PARP inhibitors developed by various companies haven't always done well in trials — or even always been PARP inhibitors.

But Lowe reports that Tesaro announced yesterday that neraparib, which it licensed from Merck, has shown promising results in ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.